As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.

This leaflet answers some common questions about Neulasta. It does not contain all the available information. It does not take the place of talking to your doctor, nurse or pharmacist. All ...

NEW YORK, NY / ACCESSWIRE / April 19, 2024 / Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching ...

H ealth Canada has granted approval to Nora Pharma for the commercialisation of its first biosimilar product, Niopeg (a ...

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network saved upwards of ...

"A parent from another kindergarten class was waiting outside the school when I took my own class out for pickup. Her child's ...

REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective ...

NIOPEG® is a Biosimilar comparable to the reference biologic drug NEULASTA® (pegfilgrastim). NIOPEG® is a long-acting form of ...